Soffinova Partners

MastOR SAS is a medical device company based in Paris, France, founded in 2019. The company focuses on developing a surgical robot designed to assist with laparoscopy, a minimally invasive surgical technique. This innovative platform aims to enhance access to advanced surgical procedures for surgeons and improve resource utilization in operating rooms. By providing tools that facilitate laparoscopy, MastOR seeks to advance surgical practices and patient care.

Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.

Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, that specializes in developing biocatalysts for the fermentation of fine chemicals. Founded in 2012, the company utilizes a patent-pending high-throughput screening technology to create biocatalysts with remarkable speed and efficiency. By focusing on tailored biocatalytic processes, Biosyntia enables the production of complex chemical compounds through fermentation, significantly reducing both production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers of fine chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives, to promote sustainable manufacturing practices and contribute to a greener future. Biosyntia is located at the Novo Nordisk Foundation Center for Biosustainability, approximately 25 kilometers north of Copenhagen.

Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact. The company currently works on four development programs: germination, flowering, growth, and weed control.

MastOR SAS is a medical device company based in Paris, France, founded in 2019. The company focuses on developing a surgical robot designed to assist with laparoscopy, a minimally invasive surgical technique. This innovative platform aims to enhance access to advanced surgical procedures for surgeons and improve resource utilization in operating rooms. By providing tools that facilitate laparoscopy, MastOR seeks to advance surgical practices and patient care.

GFBiochemicals is the only company to produce levulinic acid at commercial scale directly from biomass. In 2008, a group of biobased chemical experts saw the significant potential of levulinic acid to replace petroleum-based products across a range of market sectors. GFBiochemicals was founded to develop the production technology needed for this revolution in chemicals and biofuels. GFBiochemicals demonstrated these breakthrough technologies in the Caserta plant, in partnership with the University of Pisa and the Polytechnic University of Milan. This commercial-scale plant was retrofitted with new conversion, recovery and purification technology.

Prometheus Materials develops bio-cement with zero carbon emissions to reduce the global CO2 emissions. It aims to push the world towards sustainability. The company was founded in 2021 and is based in Boulder, Colorado.

LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.

Elicit Plant is an agro-biotech company specialized in crops’ water resistance and in the development of innovative phytosterol-based solutions.

SafeHeal is a medtech company focused on developing innovative medical devices specifically for digestive surgery. Established by MD Start, a medtech accelerator that brings physician inventions to market, SafeHeal has received funding from both MD Start and Sofinnova Partners. The company has been recognized for its contributions to the field, receiving accolades such as the Worldwide Innovation Challenge laureate in 2015 and the Charles Foix grant for its innovations aimed at enhancing the quality of life for elderly individuals. SafeHeal was also acknowledged as the most promising MedTech start-up at the Biovision 2016 investor conference and was a finalist in the global Medtech Innovator competition in 2016.

Endoron Medical specializes in the development of innovative medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company has created an endovascular suture-like device designed for use in endovascular aneurysm repair. This fixation device enhances the performance of endografts, providing a more effective and durable sealing solution. By leveraging advanced technology, Endoron Medical aims to facilitate better patient outcomes during procedures for abdominal aortic aneurysms, thereby addressing a critical need in vascular surgery.

Meiogenix SAS operates as a biotech company that develops breeding and genomic technologies. It offers SpiX technology, which modulates the process of homologous recombination in the genome by increasing its frequency in cold regions and PhoeniX, which is a non-GM method that induces meiotic recombination in hybrid diploid (or polyploid) yeast cells without the need to go through the entire process of meiosis. The company helps to develop new products to address global food and industrial challenges. The company was incorporated in 2010 and is based in Paris, France.

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.

Home Biosciences is a European venture builder focused on the biotechnology sector. The company aims to facilitate scientific breakthroughs by employing an asset-centric operating model. It provides essential funding and operational support, allowing project teams to concentrate on their core objectives. By assembling the appropriate expertise and structure, Home Biosciences helps to foster the growth of sustainable biotech ventures.

Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.

Sphere Fluidics Limited is a new Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, a novel aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its promising clinical candidates, CinCor Pharma seeks to gain marketing approval for innovative therapies that can effectively address unmet medical needs in these critical areas of health.

iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumor cells. By systematically screening human tumor cells, the Company has already identified a number of novel targets and analyzed their mode of action. The Company was founded on the successful concept of cancer immune-checkpoint therapy, which works by breaking down the inherent resistance mechanisms of tumors against immune attack. Immune resistance of tumors is often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells. Reactivating the host immune response by neutralizing these negative interactions is the idea behind cancer immune-checkpoint therapy.

TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.

Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.

Comet Biorefining, Inc. is based in London, Canada, and specializes in the development of sustainable ingredients from agricultural waste materials. The company focuses on converting non-food sources such as wood, wheat straw, bagasse, and corn stover into high-purity cellulosic glucose syrup. This innovative technology provides a cost-competitive alternative to traditional food-based sugar sources like corn or sugar cane, ensuring price stability and lower costs. In addition to its glucose products, Comet Biorefining offers biomass conversion and pretreatment services, along with a range of consulting services that include process development, engineering, and project development. The company is currently focused on scaling up its commercial operations and establishing partnerships within the renewable biofuels and biochemicals industries.

Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact. The company currently works on four development programs: germination, flowering, growth, and weed control.

Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.

AAVantgarde Bio is focused on developing innovative gene therapies specifically for inherited retinal disorders. The company utilizes proprietary Adeno-Associated Viral (AAV) vector platforms to overcome the limitations associated with the cargo capacity of traditional AAV vectors. This technology allows for the delivery of larger genes to both ocular and non-ocular tissues, enhancing the potential for effective treatment in patients. By addressing these challenges, AAVantgarde Bio aims to advance the field of gene therapy and improve outcomes for individuals affected by genetic eye diseases.

Alia Therapeutics is developing next-generation gene-editing medicines to cure rare genetic diseases.

Borea Therapeutics is advancing a new generation of gene therapies that would enable the targeting of specific tissues and cells.

Mainstay Medical Holdings plc is a medical device company based in Dublin, Ireland, with operations in the United States and Australia. Founded in 2008, the company is dedicated to developing and commercializing innovative therapies for chronic low back pain, a condition affecting a significant portion of the population. Its flagship product, ReActiv8, is an implantable neurostimulation system that aims to restore control to the muscles stabilizing the lumbar spine. Mainstay Medical collaborates with scientists and clinical experts to address the unmet needs of patients suffering from debilitating back pain, combining expertise in engineering and clinical development to deliver effective solutions in this challenging medical area.

CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.

Noema Pharma is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address the most disabling symptoms associated with conditions such as Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By prioritizing patient needs, Noema Pharma seeks to create effective treatments that significantly improve the quality of life for individuals suffering from these challenging conditions.

Catamaran Bio, Inc. develops CAR-NK immune cell therapies for the treatment of tumor. The company develops Tailwind platform to engineer, expand, and process NK cells into allogenic CAR-NK cell therapy shelf products. Catamaran Bio, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

Myricx Bio is a drug discovery company based in Stevenage, United Kingdom, that specializes in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT). Founded in 2019, the company focuses primarily on oncology while also exploring applications in other diseases such as inflammatory conditions, epilepsy, and Alzheimer’s disease. By targeting N-myristoyl transferase, Myricx Bio aims to unlock new therapeutic potentials, providing precision medicines that can specifically kill cancer cells and address viral infections. Through its innovative approach, the company seeks to deliver effective treatments for a diverse range of health conditions.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for mitochondrial and neurodegenerative diseases affecting the eye and central nervous system. The company's lead product candidates include GS010, an AAV2-based gene therapy currently undergoing Phase III clinical trials for treating Leber hereditary optic neuropathy linked to mutations in the ND4 gene, and GS030, which is in Phase I/II trials aimed at addressing retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. In addition to these candidates, GenSight Biologics is advancing other products in preclinical stages targeting various ophthalmic and neurodegenerative conditions. The company was founded in 2012 and remains dedicated to developing innovative approaches to prevent retinal degeneration and restore vision in patients with severe vision impairment or blindness.

Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.

Enthera S.r.l. is a biotechnology company based in Milan, Italy, founded in 2016. The company focuses on developing innovative therapeutic approaches for diabetes and related gastrointestinal complications, particularly enteropathy, along with other intestinal disorders that share similar biological pathways. Enthera operates a monoclonal antibody discovery platform to create first-in-class biologics aimed at addressing these underserved conditions. The company was established as a subsidiary of BiovelocITA S.r.l. and was founded in collaboration with scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio. The name "Enthera" is derived from a combination of the terms "entero," referring to the intestine, and "therapy," reflecting its commitment to developing targeted treatments.

Pixium Vision is a bioelectronics company based in Paris, France, focused on developing retinal implant systems to restore sight for individuals blinded by retinal degenerative diseases. The company is known for its PRIMA System, a bionic vision solution designed to treat blindness caused by the degeneration of photoreceptor cells in the retina. Pixium's initial device, the IRIS1, utilizes an epi-retinal implant and is undergoing clinical trials aimed at obtaining regulatory approval. A second-generation device, IRIS2, is in development, promising enhanced visual acuity through advanced technologies. Additionally, the company is working on IRIS3, a sub-retinal implant that aims to significantly improve vision compared to its predecessors. Established in 2011 as a spin-out from the Vision Institute and Université Pierre et Marie Curie, Pixium collaborates with several prestigious institutions, including Stanford University and Moorfields Eye Hospital, and is supported by prominent European venture capital firms.

MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.

Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.

NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Founded in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome, a multi-protein complex involved in the body's immune response. NodThera aims to address a variety of inflammatory and neuroinflammatory diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. Through its innovative approach to inflammasome research, NodThera seeks to contribute to the advancement of therapeutic options for these conditions.

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

CorVent Medical is developing smart, versatile, lifesaving ventilators for critical care. The company's first product, the CorVent™ Single-Use Ventilator, was designed in partnership with Design Catapult, an industrial design firm recognized for their rapid ideation of medical and commercial products. The ventilator is currently pending Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA) for ventilators, tubing connectors and accessories, which authorizes its use for the duration of the U.S. Health and Human Services COVID-19 public health emergency declaration.

PinCell is a biotech company focused on the research of therapeutic molecules based on new targets related to the pathomechanisms of inflammatory and neoplastic skin diseases.

Pyrowave Inc. is a Canadian company that specializes in advanced recycling technology solutions, utilizing microwave-based chemical processes to convert post-consumer and post-industrial plastics into high-value liquid products. Founded in 2014 and headquartered in Oakville, the company employs a patented high-power microwave catalytic depolymerization technology, which restores plastics to their molecular state, indistinguishable from virgin materials. This innovative approach facilitates the infinite recycling of plastics, addressing the growing need for sustainable waste management. Pyrowave serves a diverse clientele, including municipal clients, private recyclers, and generators, by leasing its recycling machines and providing the resultant products from its processing operations.

Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.

Epsilen Bio Srl, founded in December 2019 and based in Milan, Italy, focuses on developing innovative therapies for patients with underserved medical conditions. The company is dedicated to creating transformative treatments through a process known as epigenetic silencing, which aims to achieve stable genomic silencing of genes implicated in various pathological processes. By targeting these specific genes, Epsilen Bio seeks to address significant unmet medical needs and improve patient outcomes.

Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.

EnginZyme AB is a biotechnology company based in Stockholm, Sweden, founded in 2014. It specializes in biocatalysis and offers a cell-free synthetic biology platform to develop sustainable alternatives to conventional materials such as plastics, nylons, and rubbers. By providing solutions that facilitate the easy and cost-effective implementation of biocatalytic processes, EnginZyme aims to support the transition of the chemical industry toward more sustainable practices. The company serves a diverse range of sectors, including pharmaceuticals, food, chemicals, and flavors and fragrances, with the mission of positioning biocatalysis as the preferred choice for chemical process designers globally.

Pi-Cardia is a medical device start-up focused on developing an innovative catheter designed to treat aortic stenosis. The company’s proprietary technology utilizes a low-profile trans-femoral catheter that incorporates nitinol elements to deliver mechanical impact, creating fractures in calcified heart valves without damaging the surrounding soft tissues. This procedure, which takes only a few seconds, aims to increase the effective orifice area of the valve, providing a less invasive alternative to valve replacement. Pi-Cardia's approach seeks to offer a cost-effective and durable treatment option for patients suffering from this condition.

RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.

Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS. Redx Pharma has three subsidiaries: Redx Oncology Ltd launched in April 2012, Redx Anti-Infectives Ltd launched in April 2013 and Redx Immunology Ltd launched in May 2015.

Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

Chroma Medicine is a new genomic medicine company working on epigenetic editing. Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to revolutionize the treatment of genetically driven diseases.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for mitochondrial and neurodegenerative diseases affecting the eye and central nervous system. The company's lead product candidates include GS010, an AAV2-based gene therapy currently undergoing Phase III clinical trials for treating Leber hereditary optic neuropathy linked to mutations in the ND4 gene, and GS030, which is in Phase I/II trials aimed at addressing retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. In addition to these candidates, GenSight Biologics is advancing other products in preclinical stages targeting various ophthalmic and neurodegenerative conditions. The company was founded in 2012 and remains dedicated to developing innovative approaches to prevent retinal degeneration and restore vision in patients with severe vision impairment or blindness.

DMC Biotechnologies, Inc., a biotechnology company, develops bio-based products using microbial fermentation technology. The company's technology for engineering of microbial hosts enables the production of specialty chemicals, flavors, fragrances, nutraceuticals, natural products, and pharmaceuticals. It develops and deploys Dynamic Metabolic Control technology that reduces the cost and development timeline from discovery to commercial performance. DMC Biotechnologies, Inc. was founded in 2017 and is based in Boulder, Colorado.

TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.

Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.

Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.

Comet Biorefining, Inc. is based in London, Canada, and specializes in the development of sustainable ingredients from agricultural waste materials. The company focuses on converting non-food sources such as wood, wheat straw, bagasse, and corn stover into high-purity cellulosic glucose syrup. This innovative technology provides a cost-competitive alternative to traditional food-based sugar sources like corn or sugar cane, ensuring price stability and lower costs. In addition to its glucose products, Comet Biorefining offers biomass conversion and pretreatment services, along with a range of consulting services that include process development, engineering, and project development. The company is currently focused on scaling up its commercial operations and establishing partnerships within the renewable biofuels and biochemicals industries.

Abivax is a clinical-stage biotechnology company based in Paris, France, dedicated to discovering and optimizing treatments for inflammatory diseases, viral infections, and cancer. The company is primarily focused on its lead product, ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis and Crohn’s Disease, as well as for COVID-19. Additionally, ABX464 is being evaluated in Phase IIa trials for rheumatoid arthritis and has completed Phase IIa trials aimed at achieving viral remission in HIV patients. Abivax is also developing ABX 196, an immune enhancer in Phase 1/2 trials for hepatocellular cancer, and ABX 544, a candidate for Ebola treatment based on polyclonal antibodies. Furthermore, the company is conducting research into treatments for Dengue fever, influenza, and respiratory syncytial virus. Abivax collaborates with institutions such as the French National Centre for Scientific Research and the University of Montpellier. Founded in 2013, the company aims to harness the body’s immune response to manage chronic inflammatory conditions effectively.

Microphyt is a company based in Baillargues, France, that specializes in the research, development, production, and marketing of microalgae and other photosynthetic microorganisms. Founded in 2007, Microphyt caters to various markets, including beauty care, food, health, and energy. The company focuses on creating natural algae-based products that support weight loss and promote brain health, while also engaging in industrial farming of microalgae.

AblaCare is a Paris-based company founded in 2017 that focuses on addressing infertility related to Polycystic Ovary Syndrome (PCOS). The company has developed a minimally invasive procedure designed to restore ovulation in patients with PCOS, offering a more natural and less medicalized approach to pregnancy. This innovative treatment is performed transvaginally under ultrasound guidance, eliminating the need for general anesthesia. The procedure can be conducted in a clinic setting, utilizing techniques similar to those used by fertility specialists in in vitro fertilization (IVF). Through its solution, AblaCare aims to enhance the reproductive health and pregnancy experiences of women affected by PCOS.

AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.

Comet Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company focuses on developing novel small-molecule therapies aimed at treating orphan neurological disorders through its Coenzyme metabolism platform. By targeting dysregulated Coenzyme A metabolism, Comet Therapeutics seeks to address significant unmet medical needs in the field of neurology, providing potential treatments for conditions that currently lack effective options.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, a novel aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its promising clinical candidates, CinCor Pharma seeks to gain marketing approval for innovative therapies that can effectively address unmet medical needs in these critical areas of health.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for mitochondrial and neurodegenerative diseases affecting the eye and central nervous system. The company's lead product candidates include GS010, an AAV2-based gene therapy currently undergoing Phase III clinical trials for treating Leber hereditary optic neuropathy linked to mutations in the ND4 gene, and GS030, which is in Phase I/II trials aimed at addressing retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. In addition to these candidates, GenSight Biologics is advancing other products in preclinical stages targeting various ophthalmic and neurodegenerative conditions. The company was founded in 2012 and remains dedicated to developing innovative approaches to prevent retinal degeneration and restore vision in patients with severe vision impairment or blindness.

Afyren is a sustainable chemistry company based in Saint-Beauzire, France, focused on the valorization of non-food biomass to develop environmentally friendly alternatives to petroleum-based products. Founded in 2012, the company employs innovative biotechnological processes using natural microorganisms to produce a range of bio-sourced organic acids and a high-value fertilizer. Its services extend to microbiology and bioprocess engineering, supporting various sectors including pharmaceuticals, cosmetics, green chemistry, and biopolymers. Afyren's approach aligns with the principles of a circular, low-carbon economy, emphasizing the importance of waste reduction and sustainable resource utilization.

HighLife SAS is a medtech company that specializes in developing a novel transcatheter mitral valve replacement system aimed at treating patients with mitral regurgitation. Founded in 2010 and headquartered in Paris, France, with an additional office in Irvine, California, the company focuses on providing a minimally invasive prosthetic mitral valve that can be implanted on a beating heart. This approach preserves the native valve structure and respects the surrounding anatomy, ensuring reduced trauma during surgical procedures. HighLife's technology is designed for ease and safety of use, as well as optimal treatment outcomes, allowing for delivery through a transseptal passage via the femoral vein. The system is currently undergoing clinical evaluation to assess its effectiveness in addressing severe heart conditions.

Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.

InCarda Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops transformative therapies for cardiovascular diseases that enable patients to use in the first moments of acute cardiovascular symptoms. The company develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. InCarda Therapeutics, Inc. was formerly known as Pleiades Cardio-Therapeutics, Inc. and changed its name to InCarda Therapeutics, Inc. in May 2011. The company was founded in 2009 and is based in Newark, California.

Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.

Sitryx Therapeutics is a biopharmaceutical company established in 2018 and based in Oxford, United Kingdom. It focuses on developing disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. The company aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by renowned scientists from the United States and Europe, Sitryx has garnered significant funding, including a $30 million Series A round from various specialist investors. The company is actively engaged in multiple stages of drug discovery, working on a diverse pipeline of projects aimed at addressing unmet medical needs in immunometabolism.

Enthera S.r.l. is a biotechnology company based in Milan, Italy, founded in 2016. The company focuses on developing innovative therapeutic approaches for diabetes and related gastrointestinal complications, particularly enteropathy, along with other intestinal disorders that share similar biological pathways. Enthera operates a monoclonal antibody discovery platform to create first-in-class biologics aimed at addressing these underserved conditions. The company was established as a subsidiary of BiovelocITA S.r.l. and was founded in collaboration with scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio. The name "Enthera" is derived from a combination of the terms "entero," referring to the intestine, and "therapy," reflecting its commitment to developing targeted treatments.

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Founded in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome, a multi-protein complex involved in the body's immune response. NodThera aims to address a variety of inflammatory and neuroinflammatory diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. Through its innovative approach to inflammasome research, NodThera seeks to contribute to the advancement of therapeutic options for these conditions.

Castle Biosciences, we focus on addressing this gap. We work with leading cancer institutions to in-license proprietary technologies and complete development and validation. The ultimate goal is to make these proven tests available to all individuals afflicted with a rare cancer.

Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, that specializes in developing biocatalysts for the fermentation of fine chemicals. Founded in 2012, the company utilizes a patent-pending high-throughput screening technology to create biocatalysts with remarkable speed and efficiency. By focusing on tailored biocatalytic processes, Biosyntia enables the production of complex chemical compounds through fermentation, significantly reducing both production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers of fine chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives, to promote sustainable manufacturing practices and contribute to a greener future. Biosyntia is located at the Novo Nordisk Foundation Center for Biosustainability, approximately 25 kilometers north of Copenhagen.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing precision therapies for cardiovascular and renal conditions. Established in 2014, the company operates as a subsidiary of Novo Nordisk A/S. Corvidia specializes in researching and commercializing innovative treatments for chronic kidney disease, atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. By identifying patients with unique sensitivities to specific biological pathways, Corvidia aims to advance the development of transformative therapies that address the complex interplay between cardiovascular and renal health.

EryDel S.p.A. engages in the production and commercialization of drug delivery based on the use of autologous erythrocytes. The company provides medical devices which includes red cell loader, and erykit. The company was founded in 2007 and is based in Urbino, Italy.

LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.

Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

EnobraQ is a start-up created in 2015, from a pre-competitive research project supported by Toulouse White Biotechnology (TWB). Concerned with ecological and economic considerations, EnobraQ develops breakthrough technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics.

RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.

SafeHeal is a medtech company focused on developing innovative medical devices specifically for digestive surgery. Established by MD Start, a medtech accelerator that brings physician inventions to market, SafeHeal has received funding from both MD Start and Sofinnova Partners. The company has been recognized for its contributions to the field, receiving accolades such as the Worldwide Innovation Challenge laureate in 2015 and the Charles Foix grant for its innovations aimed at enhancing the quality of life for elderly individuals. SafeHeal was also acknowledged as the most promising MedTech start-up at the Biovision 2016 investor conference and was a finalist in the global Medtech Innovator competition in 2016.

Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact. The company currently works on four development programs: germination, flowering, growth, and weed control.

Mainstay Medical Holdings plc is a medical device company based in Dublin, Ireland, with operations in the United States and Australia. Founded in 2008, the company is dedicated to developing and commercializing innovative therapies for chronic low back pain, a condition affecting a significant portion of the population. Its flagship product, ReActiv8, is an implantable neurostimulation system that aims to restore control to the muscles stabilizing the lumbar spine. Mainstay Medical collaborates with scientists and clinical experts to address the unmet needs of patients suffering from debilitating back pain, combining expertise in engineering and clinical development to deliver effective solutions in this challenging medical area.

Aledia SA develops and manufactures light-emitting diodes (LEDs). The company offers microwire LED chips based on a 3D architecture using gallium-nitride-on-silicon microwires. It provides its products for general lighting, automotive, and display applications. The company was founded in 2011 and is based in Grenoble, France with subsidiaries in Malacca, Malaysia; and Palo Alto, California.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus vector platforms. The company operates two main platforms: Vaxwave, aimed at creating prophylactic vaccines, and TheraT, which focuses on immuno-oncology therapies. Its key product candidates include HB-101, a vaccine for cytomegalovirus currently in a Phase II clinical trial for kidney transplant patients, and HB-201 and HB-202, which are in preclinical studies for treating human papillomavirus-positive cancers. Additionally, Hookipa is collaborating with Gilead Sciences to develop therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma aims to leverage its innovative technologies to elicit robust immune responses, addressing limitations found in conventional vaccine and therapeutic approaches.